<DOC>
	<DOCNO>NCT02772497</DOCNO>
	<brief_summary>The purpose show 3-month efficacy safety diabetic macular edema treat intravitreal ziv-aflibercept .</brief_summary>
	<brief_title>3 Month Outcome Ziv-aflibercept DME</brief_title>
	<detailed_description>Multi-studies show Intravitreal aflibercept ( Eylea ) effective safe diabetic macular edema ( DME ) treatment gain FDA approval expansive ziv aflibercept ( ZALTRAP ) molecule high osmilar buffer solution FDA approve colon rectus cancer treatment cost effective . Studies show intravitreal ziv aflibercept safe nontoxic despite high osmolarity even short term effect wet age relate macular degeneration .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<criteria>Patients central diabetic macular edema Best correct visual acuity 20/25 less Central macular thickness 250 micron Patients able come followup Significant renal disease , define history chronic renal failure require dialysis kidney transplant . Myocardial infarction , acute cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 4 month prior randomization For woman childbearing potential : pregnant lactate intend become pregnant within next 3 year . Macular edema present consider related ocular surgery cataract extraction Substantial cataract , opinion investigator , likely decrease visual acuity 3 line History major ocular surgery ( include vitrectomy , scleral buckle , intraocular surgery , etc . ) within prior 4 month anticipate within next 6 month follow randomization . Exam evidence severe external ocular infection , include conjunctivitis , chalazion , substantial blepharitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>DME</keyword>
	<keyword>Anti VEGF</keyword>
	<keyword>VEGF trap</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>ZALTRAP</keyword>
	<keyword>Ziv aflibercept</keyword>
</DOC>